Versartis Inc (VSAR) saw its loss widen to $29.72 million, or $0.85 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $24.23 million, or $0.82 a share. The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $29.66 million, compared with an operating loss of $24.11 million in the previous year period.
“With topline data from our Phase 3 trial in pediatric GHD on the horizon, we have increased our focus on preparing for the regulatory review process and enhancing our commercial readiness,” said Jay Shepard, chief executive officer of Versartis. “Earlier this month at ENDO 2017, we presented three-year somavaratan results demonstrating that efficacy, safety, and IGF-I response at our Phase 3 dose are in-line with daily U.S. therapy. Together with other current data, we have assembled the most comprehensive and robust data set of the long-acting growth hormone product candidates and our studies have been conducted in the major GHD markets where we intend to commercialize. We are excited by the support we have received at ENDO and in our trials from endocrinologists throughout North America, Europe, and Japan who treat a high number of GHD patients and have expressed significant interest in somavaratan.”
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
